DGXHealthcare · Diagnostics & ResearchThe 17 Wall Street analysts covering Quest Diagnostics, Inc. hold a median 12-month price target of $250 — +6.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Quest Diagnostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (99): The share price has been relatively steady.
Accruals (60): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (9): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DGX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +6.7% from it.
Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 July 2026 | JP Morgan | Maintains | Neutral | $220 → $250 |
| 25 July 2026 | UBS | Maintains | Neutral | — |
| 24 July 2026 | Baird | Maintains | Neutral | $236 → $255 |
| 24 July 2026 | Barclays | Maintains | Overweight | $230 → $250 |
| 24 July 2026 | Mizuho | Maintains | Outperform | $235 → $260 |
| 24 July 2026 | Truist Securities | Maintains | Hold | $225 → $250 |
| 24 July 2026 | UBS | Maintains | Neutral | $220 → $232 |
| 13 July 2026 | Baird | Maintains | Neutral | $232 → $236 |
| 13 July 2026 | Baird | Maintains | Neutral | — |
| 22 Apr 2026 | Baird | Maintains | Neutral | — |
| 22 Apr 2026 | Barclays | Maintains | Overweight | — |
| 22 Apr 2026 | Truist Securities | Maintains | Hold | — |
| 22 Apr 2026 | UBS | Maintains | Neutral | — |
| 8 Apr 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 12 Feb 2026 | Mizuho | Maintains | Outperform | — |
| 11 Feb 2026 | Barclays | Maintains | Overweight | — |
| 11 Feb 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 11 Feb 2026 | Jefferies | Maintains | Buy | — |
| 11 Feb 2026 | Truist Securities | Maintains | Hold | — |
| 11 Feb 2026 | UBS | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DGX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 32% of US stocks
Cheaper than 51% of US stocks
Cheaper than 31% of US stocks
Cheaper than 26% of US stocks
Higher than 53% of US stocks
Higher than 52% of US stocks
Higher than 41% of US stocks
Higher than 73% of US stocks
Higher than 68% of US stocks
Higher than 73% of US stocks
Higher than 83% of US stocks
Higher than 35% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Quest Diagnostics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Quest Diagnostics (DGX) shares rose 2.29% over the past week. The article examines whether the stock qualifies as a top pick for momentum investors.
Why it matters — A DGX watcher would care because the item highlights the stock's recent weekly price move and its potential appeal to momentum-oriented investors.
Quest Diagnostics announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on October 21, 2026, to shareholders of record on October 6, 2026. The announcement was made on August 12, 2026.
Why it matters — DGX watchers would care because the board's declaration of a regular quarterly dividend signals continued commitment to returning cash to shareholders.
Quest Diagnostics is processing over 1,500 cyclospora tests per day, a dramatic increase from its typical daily volume of 30 to 40 tests, due to an outbreak.
Why it matters — The surge in testing volume signals operational strain at Quest Diagnostics, which could impact turnaround times and resource allocation.
Quest Diagnostics president and CEO Jim Davis appeared on Fox Business' "The Claman Countdown" to discuss how the company is implementing AI to help its patients. He addressed how artificial intelligence is being used to help patients better understand their doctors.
Why it matters — DGX watchers would care because it highlights how the company is applying AI to improve patient communication and care as part of its innovation strategy.
Quest Diagnostics raised its 2026 outlook due to a surge in testing demand. The company noted that lower-margin deals and rising project costs could temper the payoff.
Why it matters — DGX watchers would care because the raised outlook signals strong demand growth, but the accompanying cost pressures could affect future margins.
The 17 Wall Street analysts covering Quest Diagnostics, Inc. have a median 12-month price target of $250, with estimates ranging from $204 to $265. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 17 analysts covering Quest Diagnostics, Inc., 9 rate it a Buy, 7 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Quest Diagnostics, Inc. 94 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Quest Diagnostics, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).
No one can know that. What the data says: the median 12-month target from 17 analysts implies +6.7% from the last close, and Ticker Nerd's factor model ranks Quest Diagnostics, Inc. 94 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Quest Diagnostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $204 to $265 over the next 12 months.
Quest Diagnostics, Inc. returned +33.7% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Quest Diagnostics Inc. is a healthcare diagnostics company that provides diagnostic testing, information, and related services for physicians, hospitals, patients, and consumers.
The most recent item we track (Zacks Investment Research, 14 Aug 2026): "Quest Diagnostics (DGX) Is Up 2.29% in One Week: What You Should Know". Quest Diagnostics (DGX) shares rose 2.29% over the past week. The article examines whether the stock qualifies as a top pick for momentum investors.
Quest Diagnostics Inc. is a healthcare diagnostics company that provides diagnostic testing, information, and related services for physicians, hospitals, patients, and consumers. Quest Diagnostics Inc. operates through its Diagnostic Information Services segment, which supports routine and specialized laboratory testing, and an All Other segment that includes risk assessment services and healthcare information technology. The company serves a broad range of customers across the healthcare system, helping support clinical decision-making, disease detection, and ongoing patient care. Quest Diagnostics Inc. plays an important role in medical diagnostics by connecting laboratory science with practical healthcare delivery through testing networks, data-driven services, and technology-enabled solutions. Based in Secaucus, New Jersey, the company is a major participant in the diagnostics and research market and is recognized for its wide reach across clinical and consumer testing needs.
CEO Mr. James E. Davis · 46,000 employees · United States · https://www.questdiagnostics.com